Associated Papers
Comparative Analysis of a Dual DNA-RNA Panel and a DNA-Only Panel for Sarcoma: Real-World Data From a Nationwide Genomic Database.
Nakata E et al.
Cancer Science, 2026
41128349 (PubMed )
Supplement: CAS-117-156-s003.xlsx › Sheet1
Somatic mutations in Middle East and North Africa breast cancer patients: a systematic review.
Abujamous L et al.
The Oncologist, 2025
40665690 (PubMed )
Supplement: oyaf205_supplementary_data.zip › SupplementaryTable3.xlsx › SupplementaryTable3
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
39516321 (PubMed )
Supplement: 44276_2024_49_MOESM4_ESM.xlsx › supplementary_table_2
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
Zakaria NH et al.
Human Genomics, 2023
Plasma ctDNA increases tissue NGS-based detection of therapeutically targetable mutations in lung cancers.
Xie J et al.
Bmc Cancer, 2023
37004022 (PubMed )
Supplement: 12885_2023_10674_MOESM1_ESM.xlsx › data
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Michels S et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2016
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.
Wong TN et al.
Nature, 2015
25487151 (PubMed )
Supplement: NIHMS635306-supplement-3.xlsx › taml.wgs.all.tier1-3.readcounts
Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma.
Seki M et al.
Cancer Research, 2014
Select a paper to view details